Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
Screen a stock
TERMINAL
TL

TLXStockTelix Pharmaceuticals Limited American Depositary Receipt

Nasdaq Global Select Market · Healthcare · AU

$8.37 last close 2026-11-20
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment TLX's does — no target price to set, unlike a price alert.

Near limit Ratio screen, 4 of 7 decided standards passing. FTSE Shariah, MSCI Islamic, Usmani are within 3 points of their line. What would change it

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-08-25
Assessed 2026-08-25
4 of 7 pass our own screen — the standards disagree
HTR non-permissible income <0.01%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 1 bullish / 1 bearish
34
of 100
Setup confidence — system conviction, not win probabilityF

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

CANDLE · SCALP
Entry
$10.07
Stop
$9.92
Target
$10.37
Risk : Reward 2.0R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 100.0% aligned
VWAPPrice below VWAP ($8.84)
VolumeRelative volume 4.6× the 20-day average
Momentum10-day rate of change -10.1%
Overall readNEUTRAL — No Edge

Telix Pharmaceuticals Limited American Depositary Receipt (TLX) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 435 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Price target
$21.61
+158.1% · 3 analysts
Institutional own.
1.0%
of shares
Momentum (10d)
-10.1%
rate of change
SMC grade
F · 34
100.0% aligned
<0.01%
Non-permissible income — HTR, from filings (2025-12-31)
F · 34
SMC grade — 100.0% timeframe alignment
-10.1%
Rate of change (10d)
$21.61
Price target (+158.1%) · 3 analysts
1.0%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to TLX’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from the status this page publishes, last on Nov 21, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2025-12-31. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $4.1B as of 2026-09-09. At the 2026-11-20 close it is about $2.9B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 13.8% (10.0% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 4.8% (3.5% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 9.98% 30.00% Pass(20.0pp buffer)
Interest-bearing investments 3.50% 30.00% Pass(26.5pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Usmani Fail 4 of 5 ratios pass
RatioValueThresholdResult
Interest-bearing debt 34.80% 33.00% Fail(1.8pp over)
Interest-bearing investments 12.19% 33.00% Pass(20.8pp buffer)
Non-liquid assets 76.71% at least 20.00% Pass(56.7pp above the floor)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Net liquid assets per share $39.4M under mkt cap $4.1B Pass
MSCI Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 34.80% 33.33% Fail(1.5pp over)
Cash + interest-bearing securities 12.19% 33.33% Pass(21.1pp buffer)
Accounts receivable 23.29% 33.33% Pass(10.0pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
FTSE Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 34.80% 33.33% Fail(1.5pp over)
Cash + interest-bearing securities 12.19% 33.33% Pass(21.1pp buffer)
Accounts receivable 23.29% 50.00% Pass(26.7pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 6.92% 33.00% Pass(26.1pp buffer)
Cash + interest-bearing securities 2.42% 33.00% Pass(30.6pp buffer)
Accounts receivable 2.21% 33.00% Pass(30.8pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 5.0pts
Usmani (% of total assets)non permissible income ratio 5.0pts
Dow Jones Islamic Market (% of 24-mo avg market cap)non permissible income ratio 5.0pts
Usmani (% of total assets)debt ratio 1.8pts
MSCI Islamic Index (% of total assets)debt ratio 1.5pts
FTSE Shariah Global Equity Index Series (% of total assets)debt ratio 1.5pts

The numbers the ratios are built from

Read from TLX's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $803.8M 2025-12-31 Revenue
Interest-bearing debtShort and long-term borrowings $405.0M 2025-12-31 Borrowings
Cash and interest-bearing securitiesCash, equivalents and marketable securities $141.9M 2025-12-31 CashAndCashEquivalents
Total assetsBalance sheet total $1.2B 2025-12-31 Assets
Market capDenominator for AAOIFI $4.1B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series not measured — —
24-month average market capDenominator for Dow Jones Islamic Market $4.2B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $0 2025-12-31 no interest-income tag reported in 3+ years (treated as $0)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2025-12-31. Income statement as of 2025-12-31. Screened 2026-09-09.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$1.2B
    Assets · balance sheet as of 2025-12-31
  • Interest-bearing debt$405.0M
    Borrowings · balance sheet as of 2025-12-31
  • Cash and interest-bearing securities$141.9M
    CashAndCashEquivalents · balance sheet as of 2025-12-31
  • Receivables$129.2M
    TradeAndOtherCurrentReceivables · balance sheet as of 2025-12-31
  • Revenue$803.8M
    Revenue · income statement as of 2025-12-31
  • Interest income (non-permissible)$0
    no interest-income tag reported in 3+ years (treated as $0) · income statement as of 2025-12-31
  • Market cap$4.1B
    Market-data quote at screen time, 2026-09-09 · not a filing figure, so no link

What changed, and when

Verdict history for TLX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for TLX has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 4 pass and 3 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2025-12-31; market cap as stored on 2026-09-09.

Within 3 points of the line

FTSE Shariah, MSCI Islamic, Usmani are within 3 points of their line.

The ratios that move with the share price

AAOIFI's debt ratio (10.0% against a 30% line) would only fail if the market cap fell by 67%, to $1.4B. At the 2026-11-20 close it would read 13.8%.

AAOIFI's investments ratio (3.5% against a 30% line) would only fail if the market cap fell by 88%, to $472.9M. At the 2026-11-20 close it would read 4.8%.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold TLX

2 of the 278 funds whose filed holdings we currently hold own TLX shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns TLX.

Other funds
FundTLX in fundFund compliant by weight
VFWPX VANGUARD FTSE ALL-WORLD EX-US INDEX FUND 0.01% 48%
DFAI Dimensional International Core Equity Market ETF 0.00% 41%

Sorted by TLX’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names TLX once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding TLX
InvestorFirmPositionWeightAs of
Israel Englander Millennium Management $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

12.8311.229.628.016.412025-11-242026-05-272026-11-20

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
8.32
S2
8.50
S1
8.60
PIVOT
8.78
R1
8.88
R2
9.06
R3
9.16

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
9.38 – 13.32
±17.36% from 11.35, made 2026-09-25 · resolves 2026-10-02
SELL
from 19 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)33.60NEUTRAL
Stochastic %K (14)0.31BUY
CCI (20)-172.86BUY
Williams %R (14)-99.69BUY
MACD (12,26,9)-0.04SELL
ROC (10)-13.08SELL
Momentum (10)-1.26SELL
EMA (10)8.99SELL
SMA (10)9.15SELL
EMA (20)9.31SELL
SMA (20)9.21SELL
EMA (30)9.60SELL
SMA (30)9.63SELL
EMA (50)9.99SELL
SMA (50)10.36SELL
EMA (100)10.28SELL
SMA (100)10.79SELL
EMA (200)9.78SELL
SMA (200)10.03SELL

About Telix Pharmaceuticals Limited American Depositary Receipt

Healthcare · Biotechnology

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

telixpharma.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-10-21

CANDLE
Type · SCALP
10.07
Entry
9.92
Stop
10.37
Target
LOSS
Outcome · exit 10.03 (-0.45%)

Stop 9.92 Now 8.37 Target 10.37

Verdict

⚪ NEUTRAL — No Edge

Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.

Scores: 1 bullish / 1 bearish

Grade verdict

No real edge — avoid

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 64
⏰ 4H BEARISH 35
🕐 1H BEARISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-10.1%
Rate of change (10d)
4.6×
Volume vs its 20-day average
-0.41
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-17 · Asset managers net 895049 (-19081)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.